Your browser doesn't support javascript.
loading
Movement disorders in MCT8 deficiency/Allan-Herndon-Dudley Syndrome.
Masnada, Silvia; Sarret, Catherine; Antonello, Clara Eleonora; Fadilah, Ala; Krude, Heiko; Mura, Eleonora; Mordekar, Santosh; Nicita, Francesco; Olivotto, Sara; Orcesi, Simona; Porta, Francesco; Remerand, Ganaelle; Siri, Barbara; Wilpert, Nina-Maria; Amir-Yazdani, Pouneh; Bertini, Enrico; Schuelke, Markus; Bernard, Geneviève; Boespflug-Tanguy, Odile; Tonduti, Davide.
Afiliación
  • Masnada S; Unit of Pediatric Neurology, V. Buzzi Children's Hospital, Milan, Italy; C.O.A.L.A (Center for diagnosis and treatment of leukodystrophies), V. Buzzi Children's Hospital, Milan, Italy. Electronic address: silvia.masnada@asst-fbf-sacco.it.
  • Sarret C; Centre de Compétence des Leucodystrophies et Leucoencéphalopathies de Cause Rare, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France. Electronic address: csarret@chu-clermontferrand.fr.
  • Antonello CE; C.O.A.L.A (Center for diagnosis and treatment of leukodystrophies), V. Buzzi Children's Hospital, Milan, Italy; Department of Paediatric Orthopaedics, V. Buzzi Children's Hospital, Milan, Italy. Electronic address: clara.antonello@asst-fbf-sacco.it.
  • Fadilah A; Department of Paediatric Neurology, Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom. Electronic address: ala.fadilah@nhs.net.
  • Krude H; Institute of Experimental Pediatric Endocrinology, Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany. Electronic address: heiko.krude@charite.de.
  • Mura E; Unit of Pediatric Neurology, V. Buzzi Children's Hospital, Milan, Italy; C.O.A.L.A (Center for diagnosis and treatment of leukodystrophies), V. Buzzi Children's Hospital, Milan, Italy.
  • Mordekar S; Department of Paediatric Neurology, Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom. Electronic address: santosh.mordekar@nhs.net.
  • Nicita F; Genetics and Rare Diseases Research Division, Unit of Neuromuscular and Neurodegenerative Disorders, Department of Neurosciences, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Electronic address: francesco.nicita@opbg.net.
  • Olivotto S; Unit of Pediatric Neurology, V. Buzzi Children's Hospital, Milan, Italy; C.O.A.L.A (Center for diagnosis and treatment of leukodystrophies), V. Buzzi Children's Hospital, Milan, Italy. Electronic address: sara.olivotto@asst-fbf-sacco.it.
  • Orcesi S; Department of Brain and Behavioural Neurosciences, University of Pavia, Pavia, Italy; Child Neurology and Psychiatry Unit, IRCCS Mondino Foundation, Pavia, Italy. Electronic address: simona.orcesi@mondino.it.
  • Porta F; Pediatric Department, Regina Margherita Hospital, Turin, Italy.
  • Remerand G; Service de Néonatologie, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.
  • Siri B; Pediatric Department, Regina Margherita Hospital, Turin, Italy; Metabolic Unit, Department Pediatrics, Bambino Gesù Children's Hospital, Italy. Electronic address: barbara.siri@unito.it.
  • Wilpert NM; Department of Neuropediatrics, Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany. Electronic address: nina-maria.wilpert@charite.de.
  • Amir-Yazdani P; Child Health and Human Development Program, Research Institute of the McGill University Health Center, Montréal, Québec, Canada; Université Laval, Québec, Québec, Canada. Electronic address: pouneh.amir-yazdani.1@ulaval.ca.
  • Bertini E; Genetics and Rare Diseases Research Division, Unit of Neuromuscular and Neurodegenerative Disorders, Department of Neurosciences, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Electronic address: enricosilvio.bertini@opbg.net.
  • Schuelke M; Department of Neuropediatrics, Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany. Electronic address: markus.schuelke@charite.de.
  • Bernard G; Child Health and Human Development Program, Research Institute of the McGill University Health Center, Montréal, Québec, Canada; Departments of Neurology and Neurosurgery, Pediatrics and Human Genetics, McGill University, Montreal, Canada; Department Specialized Medicine, Division of Medical Genetic
  • Boespflug-Tanguy O; Department of Pediatric Neurology and Metabolic Disorders, French Reference Center for Leukodystrophies, Robert Debré Hospital, Paris, France; Inserm UMR1141 Neuroprotect, Paris Diderot University, Sorbonne Cite, Paris, France.
  • Tonduti D; Unit of Pediatric Neurology, V. Buzzi Children's Hospital, Milan, Italy; C.O.A.L.A (Center for diagnosis and treatment of leukodystrophies), V. Buzzi Children's Hospital, Milan, Italy. Electronic address: davide.tonduti@asst-fbf-sacco.it.
Mol Genet Metab ; 135(1): 109-113, 2022 01.
Article en En | MEDLINE | ID: mdl-34969638
ABSTRACT
BACKGROUND AND

OBJECTIVES:

MCT8 deficiency is a rare genetic leukoencephalopathy caused by a defect of thyroid hormone transport across cell membranes, particularly through blood brain barrier and into neural cells. It is characterized by a complex neurological presentation, signs of peripheral thyrotoxicosis and cerebral hypothyroidism. Movement disorders (MDs) have been frequently mentioned in this condition, but not systematically studied.

METHODS:

Each patient recruited was video-recorded during a routine outpatient visit according to a predefined protocol. The presence and the type of MDs were evaluated. The type of MD was blindly scored by two child neurologists experts in inherited white matter diseases and in MD. Dystonia was scored according to Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS). When more than one MD was present, the predominant one was scored.

RESULTS:

27 patients were included through a multicenter collaboration. In many cases we saw a combination of different MDs. Hypokinesia was present in 25/27 patients and was the predominant MD in 19. It was often associated with hypomimia and global hypotonia. Dystonia was observed in 25/27 patients, however, in a minority of cases (5) it was deemed the predominant MD. In eleven patients, exaggerated startle reactions and/or other paroxysmal non-epileptic events were observed.

CONCLUSION:

MDs are frequent clinical features of MCT8 deficiency, possibly related to the important role of thyroid hormones in brain development and functioning of normal dopaminergic circuits of the basal ganglia. Dystonia is common, but usually mild to moderate in severity, while hypokinesia was the predominant MD in the majority of patients.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Simportadores / Discapacidad Intelectual Ligada al Cromosoma X / Trastornos del Movimiento Tipo de estudio: Clinical_trials / Guideline Límite: Humans Idioma: En Revista: Mol Genet Metab Asunto de la revista: BIOLOGIA MOLECULAR / BIOQUIMICA / METABOLISMO Año: 2022 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Simportadores / Discapacidad Intelectual Ligada al Cromosoma X / Trastornos del Movimiento Tipo de estudio: Clinical_trials / Guideline Límite: Humans Idioma: En Revista: Mol Genet Metab Asunto de la revista: BIOLOGIA MOLECULAR / BIOQUIMICA / METABOLISMO Año: 2022 Tipo del documento: Article